Skip to main content
OpenTrials
Completed

NCT Number: NCT04403555

Ivermectin as a Novel Therapy in COVID-19 Treatment

Efficacy of Ivermectin in COVID-19 treatment

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Sherief Abd-Elsalam

Tanta, Egypt

About this study

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.

Exclusion criteria

  • Allergy or contraindication to the drugs used in the study.
  • Pregnant and lactating mothers.
  • Patients with cardiac problems.

Treatment and study plan

Ivermectin

Drug

Ivermectin treatment

Other names: iverzine, ivermectin

Primary outcomes

  1. The number of patients with mortality

    Time frame: 1 month

    Improvement of survival

Secondary outcomes

  1. Length of hospital stay

    Time frame: 1 month

    Effect on the length of hospital stay

  2. The need for mechanical ventilation

    Time frame: 1 month

    Need for mechanical ventilation

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

The Efficacy of Ivermectin in COVID-19 Treatment

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
May 27, 2020
Registry last updated
Aug 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.